Please login to the form below

Not currently logged in
Email:
Password:

AFFiRiS Alzheimer vaccine begins efficacy trial

AFFiRiS' Alzheimer's vaccine candidate AD02 has begun phase II clinical testing, with hopeful efficacy confirmation by 2012

Vienna-based AFFiRiS' Alzheimer's vaccine candidate AD02 has begun phase II clinical testing - the hope being that confirmation of its efficacy may be possible during 2012.

The start of this efficacy study comes five months after the completion of the corresponding phase I study, which confirmed the safety and tolerability of the vaccine. The company is currently developing a total of 12 prospective products in different disease areas. These are in all stages of the development pipeline.

The prospective Alzheimer's vaccine AD02 will be used with immediate effect in a multicentre phase II clinical study in Austria and five other European countries. Clinical centres in Germany, France, the Czech Republic, Slovakia and Croatia are taking part in the study, with a total of 420 patients being recruited. Information about registering for the trial appears on AFFiRiS' website

CEO and co-founder of the company, Dr Walter Schmidt said: "Last year AD02, along with our second prospective Alzheimer's vaccine AD01, was primarily tested in terms of its safety and tolerability. Those primary endpoints have been met by vaccine formulations. The decision to nominate AD02 for phase II testing study is based on currently still confidential results of the interim analysis of the secondary endpoints of the preceding phase I studies."

The other reason for accelerating the progress of AD02 is the company's intention to set clear priorities in respect of its broad product pipeline. The pipeline also comprises vaccines for treating atherosclerosis, hypertension and three other indications, which are currently still confidential.

In addition, AFFiRiS announced only a few weeks ago that a prospective vaccine for the treatment of Parkinson's disease will start phase I clinical studies at the beginning of 2011.

26th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics